BLTE

Belite Bio Inc ADR

154.45

Oct 20 • 3:59 PM ET +7.11 (4.83%)

154.45

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Mid NASD

Oct 19, 6:05 AMBelite Bio wins Nasdaq approval to move listing to Nasdaq Global Select Market, trading begins today under ticker BLTE

Peers: KOD OCGN ANNX OCUL IRD EYPT REGN OCS MGTX RGNX

| Held by: SPEM APIE ONEQ GXC BBC EHLS MSSM TNXT

Scroll to Statements

Index	-
Market Cap	6.22B
Enterprise Value	5.94B
Income	-102.36M
Sales	0.00M
Book/sh	19.28
Cash/sh	6.95
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	41
IPO	Apr 29, 2022

P/E	-
Forward P/E	81.29
PEG	-
P/S	-
P/B	8.01
P/C	22.22
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	50.02
Current Ratio	50.02
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-2.73
EPS next Y	1.90
EPS next Q	-0.79
EPS this Y	-37.66%
EPS next Y	159.75%
EPS next 5Y	-
EPS past 3/5Y	-54.04% -549.64%
Sales past 3/5Y	- -
EPS Y/Y TTM	-76.46%
Sales Y/Y TTM	-
EPS Q/Q	-41.19%
Sales Q/Q	-
Earnings	Aug 13 BMO
EPS/Sales Surpr.	9.89% -

Insider Own	1.80%
Insider Trans	-22.02%
Inst Own	22.24%
Inst Trans	0.72%
ROA	-21.60%
ROE	-22.10%
ROIC	-13.28%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-2.51%
SMA50	-6.07%
SMA200	-3.92%
Trades

Shs Outstand	40.27M
Shs Float	39.55M
Short Float	2.67%
Short Ratio	5.71
Short Interest	1.06M
52W High	200.00 -22.78%
52W Low	86.57 78.41%
Volatility	4.79% 3.86%
ATR (14)	6.62
RSI (14)	45.68
Beta	-1.22
Rel Volume	1.13
Avg Volume	185.14K
Volume	209,763

Perf Week	1.70%
Perf Month	-10.93%
Perf Quarter	-1.71%
Perf Half Y	-6.52%
Perf YTD	-3.44%
Perf Year	70.91%
Perf 3Y	351.08%
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	228.89
Prev Close	147.34
Price	154.45
Change %	4.83%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-04-26	Initiated	Canaccord Genuity	Buy	$303
Jan-26-26	Initiated	BofA Securities	Buy	$195
Jan-06-26	Initiated	Morgan Stanley	Overweight	$191
Dec-02-25	Upgrade	Mizuho	Neutral → Outperform	$194
Nov-24-25	Resumed	Cantor Fitzgerald	Overweight	$154
Nov-20-25	Initiated	Mizuho	Neutral	$105
Dec-14-23	Initiated	Maxim Group	Buy	$60
Jul-28-23	Initiated	Cantor Fitzgerald	Overweight	$43
Jul-26-23	Initiated	SVB Securities	Outperform	$25
Aug-01-22	Initiated	H.C. Wainwright	Buy	$58
Jul-01-22	Initiated	The Benchmark Company	Buy	$57

Show Previous Ratings

Oct-19-26 06:00AM	Belite Bio Announces Uplisting to the Nasdaq Global Select Market (GlobeNewswire)
Oct-14-26 04:00PM	Belite Bio Announces Multi-Market Submission of Marketing Authorization Applications Via the Access Consortium Pathway for Tinlarebant for the Treatment of Stargardt Disease Type 1 (GlobeNewswire)
Oct-01-26 08:00AM	Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences (GlobeNewswire)
Sep-28-26 08:00PM	Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences (GlobeNewswire)
Sep-11-26 11:36AM	Belite Bio, Inc. Sponsored ADR (BLTE)'s Technical Outlook is Bright After Key Golden Cross (Quartz)
06:00AM	Loading…
Sep-08-26 06:00AM	Belite Bio Announces Submission of New Drug Application to the Ministry of Health, Labour, and Welfare in Japan under the Sakigake Designation System for Tinlarebant for the Treatment of Stargardt Disease Type 1 (GlobeNewswire)
Sep-04-26 09:48AM	UiPath downgraded, Shell upgraded: Wall Street's top analyst calls (The Fly) +13.16%
Sep-01-26 08:00AM	Belite Bio to Participate in Four Upcoming Investor Conferences (GlobeNewswire)
Aug-24-26 04:00PM	Belite Bio to Host Virtual Commercial Day on September 2, 2026 (GlobeNewswire)
Aug-21-26 08:00AM	Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences (GlobeNewswire)
Aug-14-26 03:00AM	Belite Bio Inc (BLTE) (Q2 2026) Earnings Call Highlights: FDA Priority Review and Strong Cash ... (GuruFocus.com)
Aug-12-26 09:45PM	Belite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update (GlobeNewswire) -7.07%
Aug-11-26 04:01PM	Belite Bio Announces U.S. Food and Drug Administration Acceptance and Priority Review of New Drug Application for Tinlarebant for the Treatment of Stargardt Disease Type 1 (GlobeNewswire) +6.17%
Aug-06-26 08:00AM	Belite Bio to Host Webcast on August 13, 2026, to Discuss Second Quarter 2026 Financial Results (GlobeNewswire)
Jul-20-26 08:00AM	Belite Bio Announces Oral Presentation at the ASRS Annual Meeting Featuring Additional Positive Secondary Endpoint Data from the Phase 3 Trial of Tinlarebant in Stargardt Disease Type 1 (GlobeNewswire)
08:00AM	Loading…
Jul-15-26 08:00AM	Belite Bio to Participate in the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference (GlobeNewswire)
Jul-06-26 08:00AM	Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium (GlobeNewswire) +5.04%
07:00AM	Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences (GlobeNewswire)
Jun-12-26 09:30PM	Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 (GlobeNewswire)
Jun-02-26 08:00AM	Belite Bio to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference (GlobeNewswire) -8.21%
May-21-26 01:00AM	Belite Bio Inc (BLTE) Q1 2026 Earnings Call Highlights: Strategic Advancements Amid Rising Expenses (GuruFocus.com)
May-20-26 06:57AM	Belite Bio shares rise after first-quarter earnings outperform expectations (BLTE) (InvestorsHub)
06:00AM	Belite Bio Reports Unaudited First Quarter 2026 Financial Results and Provides a Corporate Update (GlobeNewswire)
May-18-26 04:00PM	Belite Bio Receives Orphan Drug Status for Tinlarebant in Stargardt Disease in Switzerland (GlobeNewswire)
May-15-26 08:00AM	Belite Bio Announces Oral Presentation at the 27th Fundus Disease Forum and International Retinal Symposium (Retina China 2026) (GlobeNewswire)
May-13-26 04:00PM	Belite Bio to Host Webcast on May 20, 2026, to Discuss First Quarter 2026 Financial Results (GlobeNewswire)
Apr-27-26 08:00AM	Belite Bio Announces Oral Presentation at the Retinal Therapeutics Innovation Summit (GlobeNewswire)
Apr-23-26 08:00AM	Belite Bio to Participate in Four Upcoming Investor Conferences (GlobeNewswire)
Apr-21-26 04:00PM	Belite Bio Initiates Rolling Submission of New Drug Application to the U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease (GlobeNewswire)
Mar-31-26 08:00AM	Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website (GlobeNewswire) +6.88%
08:43AM	Loading…
Mar-04-26 08:43AM	Belite Bio price target raised to $266 from $200 at Cantor Fitzgerald (TipRanks) +5.90%
Mar-03-26 12:01AM	Belite Bio Inc (BLTE) Q4 2025 Earnings Call Highlights: Strategic Advances and Financial Challenges (GuruFocus.com) -5.46%
Mar-02-26 06:27PM	Belite Bio Q4 Earnings Call Highlights (MarketBeat) -6.68%
08:00AM	Belite Bio to Participate in the Leerink Global Healthcare Conference (GlobeNewswire)
06:00AM	Belite Bio Reports Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update (GlobeNewswire)
Feb-23-26 08:00AM	Belite Bio to Host Webcast on March 2, 2026, to Discuss Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
Jan-29-26 08:00AM	Belite Bio Announces Participation at the 41st Asia-Pacific Academy of Ophthalmology Congress (APAO) (GlobeNewswire)
Jan-27-26 08:00AM	Belite Bio Completes Enrollment in the DRAGON II Clinical Trial of Tinlarebant for Stargardt Disease (STGD1) (GlobeNewswire)
Jan-26-26 09:50AM	Netflix, Meta upgraded: Wall Street's top analyst calls (The Fly)
Dec-02-25 07:22AM	Belite eyes tinlarebant approval after late-stage Stargardt success (Clinical Trials Arena)
Dec-01-25 10:37PM	Belite Bio Announces Pricing of $350.0 Million Underwritten Public Offering of American Depositary Shares (GlobeNewswire) +12.06%
06:45PM	Why Belite Bio Stock Soared on Monday (Motley Fool)
04:20PM	Belite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares (GlobeNewswire)
06:00AM	New Hope for People Living with a Disease Once Deemed Untreatable: Belite Bio Announces Positive Topline Results from the Pivotal Global, Phase 3 DRAGON Trial of Tinlarebant in Adolescents with Stargardt Disease (GlobeNewswire)
03:53AM	Belite continues ascent as Stargardt drug hits mark in late-stage trial (BioPharma Dive)
Nov-20-25 09:40AM	Astera initiated, Nasdaq upgraded: Wall Street's top analyst calls (The Fly) -9.29%
Nov-11-25 12:00AM	Belite Bio Inc (BLTE) Q3 2025 Earnings Call Highlights: Clinical Trials Progress and Financial ... (GuruFocus.com) -9.87%
Nov-10-25 08:00AM	Belite Bio Reports Third Quarter 2025 Financial Results and Provides a Corporate Update (GlobeNewswire)
Nov-03-25 08:00AM	Belite Bio to Host Webcast on November 10, 2025, to Discuss Third Quarter 2025 Financial Results (GlobeNewswire) +6.13%
Nov-02-25 09:00AM	Belite Bio Announces UK's Medicines and Healthcare Products Regulatory Agency Agrees to Conditional Marketing Authorization Application Based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant (GlobeNewswire)
Oct-29-25 08:00AM	Belite Bio to Participate in the Deutsche Bank ADR Virtual Investor Conference (GlobeNewswire) +5.35%
Oct-16-25 08:00AM	Belite Bio to Participate in the 2025 Maxim Growth Summit (GlobeNewswire) +9.61%
Oct-15-25 08:00AM	Belite Bio Announces China NMPA Agrees to New Drug Application with Priority Review based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant (GlobeNewswire)
Oct-02-25 08:18AM	3 Lesser-Known Healthcare Names With Major Upside in Store (MarketBeat)
Sep-15-25 05:17AM	Belite Bio wraps up Phase III trial of Stargardt disease treatment (Clinical Trials Arena)
Sep-12-25 08:00AM	Belite Bio Announces Completion of DRAGON, a 2-Year, Phase 3 Trial of Oral Tinlarebant in the Treatment of Stargardt Disease (GlobeNewswire)
Sep-08-25 08:00AM	Belite Bio Announces Up to $275 Million Upsized Private Placement Financing by Leading Healthcare Investors (GlobeNewswire)
Aug-27-25 08:00AM	Belite Bio to Participate in Three Upcoming Investor Conferences (GlobeNewswire)
Aug-12-25 03:07AM	Belite Bio Inc (BLTE) Q2 2025 Earnings Call Highlights: Strategic Advances Amid Rising Expenses (GuruFocus.com)
Aug-11-25 06:00AM	Belite Bio Reports Second Quarter 2025 Financial Results and Provides a Corporate Update (GlobeNewswire)
Aug-07-25 08:00AM	Belite Bio Announces Registered Direct Offering of $15 Million (GlobeNewswire)
Aug-06-25 08:00AM	Belite Bio to Participate in the H.C. Wainwright Annual Ophthalmology Virtual Conference (GlobeNewswire)
Aug-04-25 08:38AM	New Strong Sell Stocks for August 4th (Zacks) +6.19%
08:00AM	Belite Bio to Host Webcast on August 11, 2025, to Discuss Second Quarter 2025 Financial Results (GlobeNewswire)
Jul-23-25 08:00AM	Belite Bio to Participate in the BTIG Virtual Biotechnology Conference (GlobeNewswire)
Jul-22-25 06:16AM	New Strong Sell Stocks for July 22nd (Zacks)
Jul-03-25 12:01PM	Enrolment concludes in Belite Bios trial of Tinlarebant for geographic atrophy (Clinical Trials Arena)
Jul-02-25 03:00AM	Belite Bio Announces Completion of Enrollment in the Pivotal Global Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant in Geographic Atrophy (GlobeNewswire)
May-21-25 03:00AM	Belite Bio Announces FDA Granting of Breakthrough Therapy Designation for Tinlarebant for the Treatment of Stargardt Disease (GlobeNewswire)
May-16-25 08:35AM	Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing (GlobeNewswire)
May-15-25 07:01PM	Belite Bio Inc (BLTE) Q1 2025 Earnings Call Highlights: Strong Financial Position Amid Rising ... (GuruFocus.com) +8.88%
May-13-25 09:00PM	Belite Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
03:00AM	International companies to host live webcasts at Deutsche Banks Depositary Receipts Virtual Investor Conference on May 15, 2025 (GlobeNewswire)
May-12-25 08:00PM	International companies to host live webcasts at Deutsche Banks Depositary Receipts Virtual Investor Conference on May 15, 2025 (GlobeNewswire)
08:35AM	Belite Bio, Inc to Present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference May 15th (GlobeNewswire)
08:00AM	Belite Bio to Participate in Four Upcoming Investor Conferences (GlobeNewswire)
May-08-25 10:44AM	UPDATE - International companies to host live webcasts at Deutsche Banks Depositary Receipts Virtual Investor Conference on May 15, 2025 (GlobeNewswire)
08:35AM	International companies to host live webcasts at Deutsche Banks Depositary Receipts Virtual Investor Conference on May 15, 2025 (GlobeNewswire)
May-07-25 08:00AM	Belite Bio to Host Webcast on May 14, 2025, to Discuss First Quarter 2025 Financial Results (GlobeNewswire)
Apr-29-25 08:00AM	Belite Bio Announces Poster Presentations at the Association for Research in Vision and Ophthalmology 2025 Annual Meeting (GlobeNewswire)
Mar-17-25 06:00AM	Belite Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
06:00AM	Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website (GlobeNewswire)
Mar-11-25 03:00AM	Belite Bio to Host Webcast on March 17, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Mar-04-25 08:00AM	Belite Bio to Participate in the Leerink Partners Global Healthcare Conference (GlobeNewswire)
Feb-27-25 02:00AM	Belite Bio Announces Interim Analysis Results from the Pivotal Global Phase 3 DRAGON trial of Tinlarebant in Adolescent Stargardt Disease Subjects (GlobeNewswire)
Feb-05-25 10:35PM	Belite Bio Announces Registered Direct Offering of $15 Million (GlobeNewswire)
Nov-27-24 03:00AM	Lin BioScience Receives U.S. FDA Fast Track Designation For LBS-007 (GlobeNewswire) +5.34%
Nov-12-24 01:00AM	Belite Bio Reports Third Quarter 2024 Financial Results and Provides a Corporate Update (GlobeNewswire)
Nov-05-24 08:00AM	Belite Bio to Host Webcast on November 12, 2024, to Discuss Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-03-24 04:00PM	Belite Bio Announces Exercise of Warrants for US$28.75 Million Gross Proceeds (GlobeNewswire)
Oct-14-24 08:00AM	Belite Bio Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting (GlobeNewswire)
Oct-08-24 08:00AM	Belite Bio to Participate in the Maxim Group 2024 Healthcare Virtual Summit (GlobeNewswire) +5.93%
Sep-26-24 08:51AM	Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing (GlobeNewswire)
Sep-19-24 02:30AM	International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024 (GlobeNewswire)
Sep-17-24 11:22AM	International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024 (GlobeNewswire)
Sep-10-24 08:00AM	Belite Bio Announces First Patient Dosed in Phase 2/3 DRAGON II Trial of Tinlarebant for the Treatment of Stargardt Disease (GlobeNewswire)
Sep-03-24 08:00AM	Belite Bio to Participate in Three Upcoming Investor Conferences (GlobeNewswire)
Sep-01-24 08:00AM	Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer (GlobeNewswire)
Aug-09-24 09:52PM	BLTE Stock Earnings: Belite Bio Misses EPS for Q2 2024 (InvestorPlace)
04:30PM	Belite Bio Reports Second Quarter 2024 Financial Results and Provides a Corporate Update (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Scholl Hendrik Peter	Chief Medical Officer	Oct 01 '26	Sale	165.32	500	82,659	14,500	Oct 05 07:27 PM
Hendrik Peter Scholl	Officer	Oct 01 '26	Proposed Sale	169.82	4,000	679,280		Oct 01 06:04 PM
Lin Yu-Hsin	Chief Executive Officer	Sep 04 '26	Sale	187.71	74,435	13,972,063	96,134	Sep 09 07:39 PM
Lin Yu-Hsin	Chief Executive Officer	Sep 08 '26	Sale	196.56	26,000	5,110,486	70,134	Sep 09 07:39 PM
Chuang Hao-Yuan	Chief Financial Officer	Sep 04 '26	Sale	187.64	49,433	9,275,389	44,000	Sep 09 07:38 PM
Chuang Hao-Yuan	Chief Financial Officer	Sep 08 '26	Sale	196.42	17,962	3,528,139	26,038	Sep 09 07:38 PM
Chuang Hao-Yuan	Chief Financial Officer	Aug 12 '26	Sale	180.35	367	66,187	93,433	Aug 14 06:10 AM
Lin Yu-Hsin	Chief Executive Officer	Aug 12 '26	Sale	180.35	365	65,827	170,569	Aug 14 06:10 AM
Yu-Hsin Lin	CEO, Chairman	Aug 12 '26	Proposed Sale	177.58	126,800	22,517,144		Aug 12 05:13 PM
Hao-Yuan Chuang	Officer, Director	Aug 12 '26	Proposed Sale	177.58	93,800	16,657,004		Aug 12 05:12 PM
Scholl Hendrik Peter	Chief Medical Officer	Jun 18 '26	Sale	145.24	10,000	1,452,435	15,000	Jun 22 06:05 AM
Dr. Hendrick P. Scholl	Affiliate	Jun 18 '26	Proposed Sale	148.34	10,000	1,483,400		Jun 18 04:27 PM
Scholl Hendrik Peter	Chief Medical Officer	Jun 16 '26	Sale	140.57	10,000	1,405,729	25,000	Jun 17 06:03 AM
Dr. Hendrick P. Scholl	Affiliate	Jun 16 '26	Proposed Sale	144.24	10,000	1,442,400		Jun 16 07:10 PM
MATA NATHAN L.	Chief Scientific Officer	May 07 '26	Sale	153.21	666	102,039	0	May 08 04:45 PM
MATA NATHAN L.	Chief Scientific Officer	May 06 '26	Sale	153.84	1,000	153,839	666	May 07 04:15 PM
MATA NATHAN L.	Chief Scientific Officer	May 05 '26	Sale	155.50	1,000	155,502	1,666	May 06 04:15 PM
MATA NATHAN L.	Chief Scientific Officer	May 04 '26	Sale	155.64	1,000	155,636	2,666	May 05 04:15 PM
MATA NATHAN L.	Chief Scientific Officer	May 01 '26	Sale	155.78	1,000	155,778	3,666	May 04 04:15 PM
MATA NATHAN L.	Chief Scientific Officer	Apr 30 '26	Sale	156.97	1,000	156,973	4,666	May 01 04:15 PM
MATA NATHAN L.	Chief Scientific Officer	Apr 29 '26	Sale	155.82	1,000	155,817	5,666	Apr 30 04:15 PM
MATA NATHAN L.	Chief Scientific Officer	Apr 28 '26	Sale	159.16	1,000	159,162	6,666	Apr 29 04:32 PM
MATA NATHAN L.	Chief Scientific Officer	Apr 27 '26	Sale	162.64	1,000	162,641	7,666	Apr 28 04:28 PM
MATA NATHAN L.	Chief Scientific Officer	Apr 24 '26	Sale	159.56	1,000	159,556	8,666	Apr 27 04:52 PM
MATA NATHAN L.	Chief Scientific Officer	Apr 23 '26	Sale	166.28	1,000	166,284	9,666	Apr 24 04:15 PM
MATA NATHAN L.	Chief Scientific Officer	Apr 22 '26	Sale	170.38	1,000	170,384	10,666	Apr 23 04:19 PM
MATA NATHAN L.	Chief Scientific Officer	Apr 21 '26	Sale	166.00	1,000	166,000	11,666	Apr 22 04:15 PM
MATA NATHAN L.	Chief Scientific Officer	Apr 20 '26	Sale	163.59	1,000	163,595	12,666	Apr 21 05:28 PM
MATA NATHAN L.	Chief Scientific Officer	Apr 17 '26	Sale	161.63	1,000	161,630	13,666	Apr 20 04:15 PM
MATA NATHAN L.	Chief Scientific Officer	Apr 16 '26	Sale	160.38	1,000	160,381	14,666	Apr 20 04:15 PM
MATA NATHAN L.	Chief Scientific Officer	Apr 15 '26	Sale	168.30	1,000	168,298	15,666	Apr 16 04:15 PM
Nathan L. Mata	Officer	Apr 15 '26	Proposed Sale	171.93	16,666	2,865,385		Apr 15 05:23 PM
Lin Yu-Hsin	Chief Executive Officer	Apr 09 '26	Sale	181.45	9,200	1,669,339	170,934	Apr 13 04:15 PM
Chen Wan-Shan	Director	Apr 09 '26	Sale	180.43	1,100	198,473	9,096	Apr 13 04:15 PM
Chuang Hao-Yuan	Chief Financial Officer	Apr 09 '26	Sale	181.50	6,200	1,125,303	93,800	Apr 13 04:15 PM
Yu-Hsin Lin	CEO, Chairman	Apr 09 '26	Proposed Sale	178.73	136,000	24,307,280		Apr 09 04:52 PM
Hao-Yuan Chuang	Officer, Director	Apr 09 '26	Proposed Sale	178.73	100,000	17,873,000		Apr 09 04:43 PM
Wan Shan Chen	affiliate	Apr 09 '26	Proposed Sale	217.76	10,196	2,220,250		Apr 09 12:17 PM

Belite Bio, Inc. engages in the research and development of drugs. It focuses on the treatment of eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease. It also caters to metabolic diseases such as non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, type 2 diabetes, and gout. The company was founded by Yu-Hsin Lin on March 27, 2018 and is headquartered in San Diego, CA.

Ph.D.Dr. Yu-Hsin Lin M.B.A.

F.R.M.Mr. Hao-Yuan Chuang C.F.A.

Chief Scientific OfficerDr. Nathan L. Mata Ph.D.

M.D.Dr. Hendrik P.N. Scholl M.A.

Chief Commercial OfficerMs. Kelly Kilpatrick

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BLTE

Belite Bio Inc ADR

Upgrade your Finviz experience